CERo Therapeutics Holdings, Inc. Common Stock (CERO) - Total Liabilities
Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) has total liabilities worth $32.41 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CERO financial resilience to evaluate the company's liquid asset resilience ratio.
CERo Therapeutics Holdings, Inc. Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CERo Therapeutics Holdings, Inc. Common asset portfolio.
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of CERo Therapeutics Holdings, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kollect on Demand Holding Ab
ST:KOLL
|
Sweden | Skr10.37 Million |
|
Tinybuild Inc
LSE:TBLD
|
UK | GBX11.51 Million |
|
Strikewell Energy Corp
V:SKK
|
Canada | CA$28.37 Million |
|
ProstaLund AB
ST:PLUN
|
Sweden | Skr11.30 Million |
|
Glen Eagle Resources Inc
V:GER
|
Canada | CA$4.08 Million |
|
EUROPA MET. LTD POST CONS
F:WRE1
|
Germany | €67.11K |
|
Satis Group S.A.
WAR:STS
|
Poland | zł274.74 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down CERo Therapeutics Holdings, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is CERo Therapeutics Holdings, Inc. Common 's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 17.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CERo Therapeutics Holdings, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.09 Million | +12.17% |
| 2024-12-31 | $8.10 Million | -82.83% |
| 2023-12-31 | $47.18 Million | +18.26% |
| 2022-12-31 | $39.90 Million | +331.42% |
| 2021-12-31 | $9.25 Million | -- |
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.